Wrinkles
Conditions
Keywords
Periorbital wrinkles, Efficacy and safety
Brief summary
The purpose of this study is to determine whether La Jolie gel is effective in the treatment of periorbital wrinkles.
Detailed description
Argireline has mechanism of action that significantly inhibited neurotransmitter release with a potency similar to that of BoNTA. Inhibition of neurotransmitter release was due to the interference of the hexapeptide with the formation and/or stability of SNARE complex. Notably, this peptide did not exhibit in vivo oral toxicity nor primary irritation at high doses. These findings demonstrate that Argireline is a anti-wrinkle peptide that emulates the action of currently used BoNTs. In vivo study, Topical Argireline 10% is applied on lateral preorbital area twice daily for 30 days. The result demonstrates a significant anti-wrinkle activity by decreased skin wrinkle 30%. These findings demonstrate a significant anti-wrinkle activity for Argireline, in agreement with its in vitro and cellular activities. Topical Argireline represents a bio-safe alternative to BoNTs in anti-wrinkle therapy.
Interventions
DRUG10% Argireline
10% Argireline (La jolie gel®, Pacific health care, Thailand) were instructed to apply the gel over the face and periorbital area twice daily for a period of 3 months.
Sponsors
Pacific Health Foundation
Mahidol University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
35 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* healthy woman at 35-45 years old * Presence of periorbital wrinkles
Exclusion criteria
* Pregnancy * Nursing * Keloids /scar at periorbital area * pre-treatment with topical periorbital products within 1 month * Botulinum toxin A injection,facial plastic surgery within 1 year * Allergic to active ingredients including acetyl hexapeptide-3 Argireline®, sodium hyaluronate,adenosine,arbutin,fucus vesiculosus)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy | 3 months | Objective evaluation * Noninvasive measurement by skin bioengineering technique e.g. visioscan, corneometer, cutometer * Comparative photographic evaluation by certified dermatologists Subjective evaluation * Patient Self assessment satifaction review |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety | 3 months | Number of participants with adverse events Categorized adverse events |
Countries
Thailand
Outcome results
None listed